Literature DB >> 8774285

Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report.

J S Krasnow1, S L Berga, D S Guzick, A J Zeleznik, K T Yeo.   

Abstract

OBJECTIVE: To determine whether serum levels of vascular permeability factor (VPF) are elevated in patients with ovarian hyperstimulation syndrome (OHSS) and to determine if luteinizing granulosa cells may be a source of VPF.
DESIGN: Prospective observational study.
SETTING: University IVF and GIFT program. PATIENTS: Eight consecutive IVF and GIFT patients at high risk for OHSS. MAIN OUTCOME MEASURES: Vascular permeability factor concentration in serum and follicular fluid.
RESULTS: Serum VPF was significantly higher (15.2 +/- 4.0 pM; mean +/- SEM) on day +14 in the group who developed severe OHSS compared with those who did not. Follicular fluid VPF (171.5 +/- 18.5 pM) was approximately 100-fold greater than serum (1.7 +/- 1.3 pM) or peritoneal fluid (2.5 +/- 1.3 pM) 36 hours after hCG administration.
CONCLUSION: Vascular permeability factor is elevated in patients with severe OHSS and the ovary may be a source of VPF secretion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8774285

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  12 in total

Review 1.  The pathogenesis of ovarian hyperstimulation syndrome: a continuing enigma.

Authors:  A Simon; A Revel; A Hurwitz; N Laufer
Journal:  J Assist Reprod Genet       Date:  1998-04       Impact factor: 3.412

2.  Cytokine levels in a patient with severe ovarian hyperstimulation syndrome before and after the ultrafiltration and reinfusion of ascitic fluid.

Authors:  M Ito; T Harada; T Iwabe; M Tanikawa; N Terakawa
Journal:  J Assist Reprod Genet       Date:  2000-02       Impact factor: 3.412

3.  The role of intravenous immunoglobulin in the prevention of severe ovarian hyperstimulation syndrome.

Authors:  R Orvieto; A Achiron; R Margalit; Z Ben-Rafael
Journal:  J Assist Reprod Genet       Date:  1998-01       Impact factor: 3.412

4.  Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: "tap early and often" versus hospitalization.

Authors:  John M Csokmay; Belinda J Yauger; Melinda B Henne; Alicia Y Armstrong; John T Queenan; James H Segars
Journal:  Fertil Steril       Date:  2008-11-05       Impact factor: 7.329

5.  Influence of VEGFR and LHCGR on endometrial adenocarcinoma.

Authors:  Alexandra C Kölbl; Amelie E Birk; Christina Kuhn; Udo Jeschke; Ulrich Andergassen
Journal:  Oncol Lett       Date:  2016-07-22       Impact factor: 2.967

6.  Mild/minimal stimulation protocol for ovarian stimulation of patients at high risk of developing ovarian hyperstimulation syndrome.

Authors:  L Rinaldi; F Lisi; H Selman
Journal:  J Endocrinol Invest       Date:  2014-01-08       Impact factor: 4.256

7.  Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome.

Authors:  E R Levin; G F Rosen; D L Cassidenti; B Yee; D Meldrum; A Wisot; A Pedram
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

8.  The vascular endothelial growth factor (VEGF) +405 G/C polymorphism and its relationship with recurrent implantation failure in women in an IVF programme with ICSI.

Authors:  Radia Boudjenah; Denise Molina-Gomes; Robert Wainer; Philippe de Mazancourt; Jacqueline Selva; François Vialard
Journal:  J Assist Reprod Genet       Date:  2012-10-27       Impact factor: 3.412

9.  Regulation of soluble vascular endothelial growth factor receptor (sFlt-1/sVEGFR-1) expression and release in endothelial cells by human follicular fluid and granulosa cells.

Authors:  Ruth Gruemmer; Karin Motejlek; Daniela Berghaus; Herbert A Weich; Joseph Neulen
Journal:  Reprod Biol Endocrinol       Date:  2005-10-25       Impact factor: 5.211

10.  Serum human chorionic gonadotropin is associated with angiogenesis in germ cell testicular tumors.

Authors:  Oscar Arrieta; Rosa Mayela Michel Ortega; Julián Angeles-Sánchez; Cynthia Villarreal-Garza; Alejandro Avilés-Salas; José G Chanona-Vilchis; Elena Aréchaga-Ocampo; Arturo Luévano-González; Miguel Angel Jiménez; José Luis Aguilar
Journal:  J Exp Clin Cancer Res       Date:  2009-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.